Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Influenza worsens AMI outcomes

13 Nov 2019

Patients with acute myocardial infarction (AMI) are likely to suffer from worse clinical outcomes in the presence of influenza and other viral infections, a recent study has shown.

Drawing from the National Inpatient Sample, researchers identified 1,884,985 AMI admission, 1.1 percent of whom were positive for infections. There were 9,885 AMI patients with influenza (mean age, 72.3±14.0 years; 47.8 percent female) and 11,485 with other viral respiratory infections (mean age, 71.9±14.2 years; 48.4 percent female).

Clinical outcomes were worst in patients who had concomitant influenza. In-hospital case fatality rate, for example, was highest in these patients as opposed to those with other viral respiratory infections and without any viral infections (13.5 percent vs 7.5 percent and 8.6 percent; p<0.001).

The same was true for acute respiratory failure (19.2 percent vs 10.1 percent and 10.2 percent; p<0.001), acute kidney injury (40.3 percent vs 31.0 percent and 24.2 percent; p<0.001) and length of stay (9.3±10.3 vs 7.5±8.6 and 5.8±7.3 days; p<0.001), among other important outcome measures.

These differences remained significant even after propensity-score adjustment.

Relative to those without concomitant influenza, AMI patients with the infection were more likely to die while admitted (13.2 percent vs 9.6 percent; p<0.001) and to develop acute respiratory failure (53.0 percent vs 28.8 percent; p<0.001) and acute kidney injury (40.2 percent vs 28.6 percent; p<0.001).

These findings were generally untrue in AMI patients who had other viral respiratory infections, except for acute respiratory failure, which occurred at a much higher frequency than in the no-infection comparators.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 6 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
12 Jan 2020
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.